{
    "root": "2b531051-2e0b-458a-bebc-fbcc3cb6af16",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Clozapine"
    },
    "value": "20250212",
    "ingredients": [
        {
            "name": "CLOZAPINE",
            "code": "J60AR2IKIC"
        },
        {
            "name": "ASPARTAME",
            "code": "Z0H242BBR1"
        },
        {
            "name": "CROSPOVIDONE (35 .MU.M)",
            "code": "40UAA97IT9"
        },
        {
            "name": "CROSPOVIDONE (20 .MU.M)",
            "code": "6B46OH7T95"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "POLYVINYL ACETATE",
            "code": "32K497ZK2U"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "PEPPERMINT",
            "code": "V95R5KMY2B"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "SODIUM STEARYL FUMARATE",
            "code": "7CV7WJK4UI"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "Clozapine is an atypical antipsychotic indicated for: Treatment-resistant schizophrenia. Efficacy was established in an active-controlled study (1.1 , 14.1) . Reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder. Efficacy was established in an active- controlled study (1.2 , 14.2) .",
    "contraindications": "Starting Dose: 12.5 mg once daily or twice daily (2.3) . Use cautious titration and divided dosage schedule (2.3 , 5.3) . Titration: increase the total daily dosage in increments of 25 mg to 50 mg per day, if well-tolerated (2.3) . Target dose: 300 mg to 450 mg per day, in divided doses, by the end of 2 weeks (2.3) . Subsequent increases: increase in increments of 100 mg or less, once or twice weekly (2.3) . Maximum daily dose: 900 mg (2.3) . Tablets rapidly disintegrate after placement in the mouth and may be chewed if desired. No water is needed (2.3) .",
    "warningsAndPrecautions": null,
    "adverseReactions": "Clozapine orally disintegrating tablets are contraindicated in patients with a history of serious hypersensitivity to clozapine (e.g., photosensitivity, vasculitis, erythema multiforme, or Stevens-Johnson syndrome) or any other component of clozapine orally disintegrating tablets [see Adverse Reactions (6.2)]."
}